{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:01:31Z","timestamp":1790276491023,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Kyowa Kirin International"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00198-022-06432-9","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T18:02:46Z","timestamp":1653760966000},"page":"1845-1857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A literature review to understand the burden of disease in people living with tumour-induced osteomalacia"],"prefix":"10.1007","volume":"33","author":[{"given":"Salvatore","family":"Minisola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Barlassina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally-Anne","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,28]]},"reference":[{"key":"6432_CR1","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1530\/ERC-11-0006","volume":"18","author":"WH Chong","year":"2011","unstructured":"Chong WH, Molinolo AA, Chen CC, Collins MT (2011) Tumor-induced osteomalacia. Endocr Relat Cancer 18:R53-77. https:\/\/doi.org\/10.1530\/ERC-11-0006","journal-title":"Endocr Relat Cancer"},{"key":"6432_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s11926-015-0512-5","volume":"17","author":"AH Hautmann","year":"2015","unstructured":"Hautmann AH, Hautmann MG, Kolbl O, Herr W, Fleck M (2015) Tumor-induced osteomalacia: an up to-date review. Curr Rheumatol Rep 17:512. https:\/\/doi.org\/10.1007\/s11926-015-0512-5","journal-title":"Curr Rheumatol Rep"},{"key":"6432_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.afos.2018.12.001","volume":"4","author":"Z Yin","year":"2018","unstructured":"Yin Z, Du J, Yu F, Xia W (2018) Tumor-induced osteomalacia. Osteoporos Sarcopenia 4:119\u2013127. https:\/\/doi.org\/10.1016\/j.afos.2018.12.001","journal-title":"Osteoporos Sarcopenia"},{"key":"6432_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10436","volume":"5","author":"F Jerkovich","year":"2021","unstructured":"Jerkovich F, Nunez S, Mocarbel Y et al (2021) Burden of disease in patients with tumor-induced osteomalacia. JBMR Plus 5:e10436. https:\/\/doi.org\/10.1002\/jbm4.10436","journal-title":"JBMR Plus"},{"key":"6432_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00223-020-00691-6","volume":"108","author":"P Florenzano","year":"2021","unstructured":"Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT (2021) Tumor-induced osteomalacia. Calcif Tissue Int 108:128\u2013142. https:\/\/doi.org\/10.1007\/s00223-020-00691-6","journal-title":"Calcif Tissue Int"},{"key":"6432_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00223-021-00843-2","volume":"109","author":"B Abrahamsen","year":"2021","unstructured":"Abrahamsen B, Smith CD, Minisola S (2021) Epidemiology of tumor-induced osteomalacia in Denmark. Calcif Tissue Int 109:147\u2013156. https:\/\/doi.org\/10.1007\/s00223-021-00843-2","journal-title":"Calcif Tissue Int"},{"key":"6432_CR7","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jbmr.4233","volume":"36","author":"SM Jan de Beur","year":"2021","unstructured":"Jan de Beur SM, Miller PD, Weber TJ et al (2021) Burosumab for the treatment of tumor-induced osteomalacia. J Bone Miner Res 36:627\u2013635. https:\/\/doi.org\/10.1002\/jbmr.4233","journal-title":"J Bone Miner Res"},{"key":"6432_CR8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","volume":"78","author":"YN Lamb","year":"2018","unstructured":"Lamb YN (2018) Burosumab: first global approval. Drugs 78:707\u2013714. https:\/\/doi.org\/10.1007\/s40265-018-0905-7","journal-title":"Drugs"},{"key":"6432_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","volume":"105","author":"AA Portale","year":"2019","unstructured":"Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, Crowley R, Jan De Beur S, Eastell R, Imanishi Y (2019) Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int 105:271\u2013284. https:\/\/doi.org\/10.1007\/s00223-019-00568-3","journal-title":"Calcif Tissue Int"},{"key":"6432_CR10","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/jbmr.4184","volume":"36","author":"Y Imanishi","year":"2021","unstructured":"Imanishi Y, Ito N, Rhee Y, Takeuchi Y, Shin CS, Takahashi Y, Onuma H, Kojima M, Kanematsu M, Kanda H (2021) Interim analysis of a phase 2 open-label trial assessing burosumab efficacy and safety in patients with tumor-induced osteomalacia. J Bone Miner Res 36:262\u2013270. https:\/\/doi.org\/10.1002\/jbmr.4184","journal-title":"J Bone Miner Res"},{"key":"6432_CR11","doi-asserted-by":"publisher","first-page":"116064","DOI":"10.1016\/j.bone.2021.116064","volume":"152","author":"ML Brandi","year":"2021","unstructured":"Brandi ML, Clunie GPR, Houillier P, Jan de Beur SM, Minisola S, Oheim R, Seefried L (2021) Challenges in the management of tumor-induced osteomalacia (TIO). Bone 152:116064. https:\/\/doi.org\/10.1016\/j.bone.2021.116064","journal-title":"Bone"},{"key":"6432_CR12","doi-asserted-by":"publisher","unstructured":"Dahir K, Zanchetta MB, Stanciu I et al (2021) Diagnosis and management of tumor-induced osteomalacia: perspectives from clinical experience. J Endocr Soc 5:bvab099. https:\/\/doi.org\/10.1210\/jendso\/bvab099","DOI":"10.1210\/jendso\/bvab099"},{"key":"6432_CR13","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/jbmr.1642","volume":"27","author":"Y Jiang","year":"2012","unstructured":"Jiang Y, Xia WB, Xing XP et al (2012) Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature. J Bone Miner Res 27:1967\u20131975. https:\/\/doi.org\/10.1002\/jbmr.1642","journal-title":"J Bone Miner Res"},{"key":"6432_CR14","unstructured":"Flourish Flourish Data Visualization & Storytelling. https:\/\/www.flourish.studio\/ Accessed 11 Jan 2022"},{"key":"6432_CR15","doi-asserted-by":"publisher","first-page":"e1546","DOI":"10.7759\/cureus.1546","volume":"9","author":"JW Sayre","year":"2017","unstructured":"Sayre JW, Toklu HZ, Ye F, Mazza J, Yale S (2017) Case reports, case series - from clinical practice to evidence-based medicine in graduate medical education. Cureus 9:e1546. https:\/\/doi.org\/10.7759\/cureus.1546","journal-title":"Cureus"},{"key":"6432_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853.17","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med 23:60\u201363. https:\/\/doi.org\/10.1136\/bmjebm-2017-110853.17","journal-title":"BMJ Evid Based Med"},{"key":"6432_CR17","doi-asserted-by":"publisher","unstructured":"Feng J, Jiang Y, Wang O, Li M, Xing X, Huo L, Li F, Yu W, Zhong D-r, Jin J (2017) The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocrine J EJ16\u20130587. https:\/\/doi.org\/10.1507\/endocrj.EJ16-0587","DOI":"10.1507\/endocrj.EJ16-0587"},{"key":"6432_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12891-017-1756-1","volume":"18","author":"Q-y Zuo","year":"2017","unstructured":"Zuo Q-y, Wang H, Li W, Niu X-h, Huang Y-h, Chen J, You Y-h, Liu B-y, Cui A-m, Deng W (2017) Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients. BMC Musculoskeletal Disord 18:1\u20139. https:\/\/doi.org\/10.1186\/s12891-017-1756-1","journal-title":"BMC Musculoskeletal Disord"},{"key":"6432_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12874-018-0495-9","volume":"18","author":"M Mueller","year":"2018","unstructured":"Mueller M, D\u2019Addario M, Egger M, Cevallos M, Dekkers O, Mugglin C, Scott P (2018) Methods to systematically review and meta-analyse observational studies: a systematic scoping review of recommendations. BMC Med Res Methodol 18:1\u201318. https:\/\/doi.org\/10.1186\/s12874-018-0495-9","journal-title":"BMC Med Res Methodol"},{"key":"6432_CR20","doi-asserted-by":"publisher","unstructured":"Nakamura T, Igarashi H, Ito T, Jensen RT (2014) Important [sic] of case-reports\/series, in rare diseases: using neuroendocrine tumors as an example. World J Clin Cases 2:608\u2013613. https:\/\/doi.org\/10.12998\/wjcc.v2.i11.608","DOI":"10.12998\/wjcc.v2.i11.608"},{"key":"6432_CR21","doi-asserted-by":"publisher","unstructured":"Sampayo-Cordero M, Miguel-Huguet B, Malfettone A, Perez-Garcia JM, Llombart-Cussac A, Cortes J, Pardo A, Perez-Lopez J (2020) The value of case reports in systematic reviews from rare diseases. The example of enzyme replacement therapy (ERT) in patients with mucopolysaccharidosis type II (MPS-II). Int J Environ Res Public Health 17:(18):E6590. https:\/\/doi.org\/10.3390\/ijerph17186590.","DOI":"10.3390\/ijerph17186590"},{"key":"6432_CR22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2147\/JPR.S105892","volume":"9","author":"M Due\u00f1as","year":"2016","unstructured":"Due\u00f1as M, Ojeda B, Salazar A, Mico JA, Failde I (2016) A review of chronic pain impact on patients, their social environment and the health care system. J Pain Res 9:457\u2013467. https:\/\/doi.org\/10.2147\/JPR.S105892","journal-title":"J Pain Res"},{"key":"6432_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/2374373518786013","volume":"6","author":"MA Hadi","year":"2019","unstructured":"Hadi MA, McHugh GA, Closs SJ (2019) Impact of chronic pain on patients\u2019 quality of life: a comparative mixed-methods study. J Patient Exp 6:133\u2013141. https:\/\/doi.org\/10.1177\/2374373518786013","journal-title":"J Patient Exp"},{"key":"6432_CR24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/00002508-199706000-00006","volume":"13","author":"DA Fishbain","year":"1997","unstructured":"Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS (1997) Chronic pain-associated depression: antecedent or consequence of chronic pain? A review. Clin J Pain 13:116\u2013137. https:\/\/doi.org\/10.1097\/00002508-199706000-00006","journal-title":"Clin J Pain"},{"key":"6432_CR25","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/HRP.0000000000000198","volume":"26","author":"WW IsHak","year":"2018","unstructured":"IsHak WW, Wen RY, Naghdechi L et al (2018) Pain and depression: a systematic review. Harv Rev Psychiatry 26:352\u2013363. https:\/\/doi.org\/10.1097\/HRP.0000000000000198","journal-title":"Harv Rev Psychiatry"},{"key":"6432_CR26","doi-asserted-by":"publisher","first-page":"232470961989516","DOI":"10.1177\/2324709619895162","volume":"7","author":"L Seemann","year":"2019","unstructured":"Seemann L, Padala SA, Mohammed A, Belayneh N (2019) Tumor-induced osteomalacia and the importance of plasma fibroblast growth factor 23 as an indicator: diagnostic delay leads to a suicide attempt. J Investig Med High Impact Case Rep 7:2324709619895162. https:\/\/doi.org\/10.1177\/2324709619895162","journal-title":"J Investig Med High Impact Case Rep"},{"key":"6432_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jbspin.2019.07.012","volume":"87","author":"AL Day","year":"2020","unstructured":"Day AL, Guti\u00e9rrez OM, Guthrie BL, Saag KG (2020) Burosumab in tumor-induced osteomalacia: a case report. Joint Bone Spine 87:81\u201383. https:\/\/doi.org\/10.1016\/j.jbspin.2019.07.012","journal-title":"Joint Bone Spine"},{"key":"6432_CR28","unstructured":"The Symposium on Hypophosphatemia: Past P, and Future, (2019) XLH Network; (Voice of the Patient Report)"},{"key":"6432_CR29","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s11136-020-02465-x","volume":"29","author":"SH Lo","year":"2020","unstructured":"Lo SH, Lachmann R, Williams A, Piglowska N, Lloyd AJ (2020) Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study. Qual Life Res 29:1883\u20131893. https:\/\/doi.org\/10.1007\/s11136-020-02465-x","journal-title":"Qual Life Res"},{"key":"6432_CR30","doi-asserted-by":"crossref","unstructured":"Linglart A, Dvorek-Ewell M, Marshall A, Martin JS, Skrinar A (2015) Impaired mobility and pain significantly impact the quality of life of children with X-linked hypophosphatemia. Bone Abstracts. Bioscientifica]. http:\/\/www.bone-abstracts.org\/ba\/0004\/ba0004p198. Accessed 11 Jan 2022","DOI":"10.1530\/boneabs.4.P198"},{"key":"6432_CR31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40290-020-00332-1","volume":"34","author":"V Boulanger","year":"2020","unstructured":"Boulanger V, Schlemmer M, Rossov S, Seebald A, Gavin P (2020) Establishing patient registries for rare diseases: rationale and challenges. Pharmaceut Med 34:185\u2013190. https:\/\/doi.org\/10.1007\/s40290-020-00332-1","journal-title":"Pharmaceut Med"},{"key":"6432_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00198-020-05548-0","volume":"32","author":"L Seefried","year":"2021","unstructured":"Seefried L, Smyth M, Keen R, Harvengt P (2021) Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review. Osteoporos Int 32:7\u201322. https:\/\/doi.org\/10.1007\/s00198-020-05548-0","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06432-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06432-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06432-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T17:39:11Z","timestamp":1662745151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06432-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,28]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["6432"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06432-9","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,28]]},"assertion":[{"value":"14 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SM works for Sapienza University of Rome. He served as a speaker for Amgen, Bruno Farmaceutici, Diasorin, Eli Lilly, Sandoz, Takeda and Kyowa Kirin and was on the advisory board of Abiogen, Kyowa Kirin, Pfizer and UCB. AB and SAV work for OPEN Health. SW and AW work for Kyowa Kirin International.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}